Drug Profile


Alternative Names: ACE-536

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Beta-thalassaemia; Myelodysplastic syndromes
  • Phase II Anaemia; Myelofibrosis
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 03 Aug 2017 Acceleron and Celgene plan the phase II BEYOND trial for Beta-thalassaemia by year-end 2017
  • 03 Aug 2017 Celgene initiates a phase II trial in Myelofibrosis and Anaemia (SC) before August 2017
  • 23 Jun 2017 Interim efficacy and adverse events data from a phase II trial in Beta-thalassaemia presented at the 22nd Congress of the European Hematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top